RxDoctor Payments Data

Rosanna Hastings, NP

Nurse Practitioner · Richmond, VANPI 1699222430

Payments from drug & device makers

$3,993in general payments, 2019–2025

Across 136 payments — averaging $29.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$900
  • Abbott$792
  • AstraZeneca$332
  • Edwards Lifesciences$253
  • Cvrx, Inc.$231
  • Impulse Dynamics (USA) Inc.$176
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,993100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,993 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$32,355
Medicare patients
145
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis16$363,565
EntrestoSacubitril/Valsartan186$155,874
JardianceEmpagliflozin84$73,905
FarxigaDapagliflozin Propanediol73$67,600
CorlanorIvabradine Hcl50$20,916
EliquisApixaban13$11,687
Bumetanide199$6,778
Isosorbide Dinitrate40$2,472
Hydralazine Hcl123$1,453
Eplerenone19$1,425
Spironolactone229$1,272
Digoxin62$1,209
Potassium Chloride65$1,083
Metoprolol Succinate133$1,005
Acetazolamide11$728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$36$375,25129 claims
NovartisEntresto$33$155,874186 claims
Boehringer IngelheimJardiance$131$73,90584 claims
AstraZenecaFarxiga$332$67,60073 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →